Message #7 From:
Stock News Bot Date: August 18, 2006 03:30:00 AM
MDSM News Medistem Appoints Former World Health Organization Microbiologist Dr. Clem Persaud to Medical Advisory Board; New Member Underscores Medistem's Commitment to Collaboration with International Authorities on Stem Cell Research
SCOTTSDALE, Ariz.--(BUSINESS WIRE)--Aug. 18, 2006--Medistem Laboratories, Inc. (OTCBB:MDSM) (FWB:S2U), committed to the ethical development of next-generation medical therapies from non-controversial adult stem cell sources, announces that Dr. Clem Persaud, a former Fellow at the World Health Organization and microbiologist, is the latest to join its medical advisory board.
Dr. Persaud is an international authority on adult stem cell and embryonic stem cell research, and has been called upon to provide his expertise at governmental levels. He co-developed and coordinated the biotechnology program at Canadore College, Ontario, Canada. He also has served as director of the Global Disaster Relief Fund in Canada.
"We are grateful for Dr. Persaud's addition to our medical advisory board," said Neil Riordan, Ph.D., CEO of Medistem. "As Medistem's affiliates continue with laboratory and clinical operations, we look forward to the guidance and perspective Dr. Persaud can provide."
"It's an exciting time to be working with Medistem as the Company works to develop fundamental science and real-world therapeutic applications," said Dr. Persaud. "I am honored to join the medical advisory board and look forward to contributing to the mission of Medistem and their desire to use cellular therapy in the treatment of devastating diseases."
About Medistem Laboratories, Inc.
Medistem Laboratories is an innovative biotechnology company committed to the creation, licensing and commercialization of advanced medical therapies based on non-controversial adult stem cells. The Company intends to use adult stem cells generated from muscle, bone marrow and fat of adult patients seeking treatment, as well as from full-term, healthy placentas and umbilical cords, which the Company believes to be non-controversial sources of stem cells. Medistem common stock is traded on the Frankfurt, Germany, stock exchange under the symbol S2U. For more information, please visit http://www.trilogy-capital.com/tcp/medistem/. To read or download Medistem's Investor Fact Sheet, please visit http://www.trilogy-capital.com/tcp/medistem/factsheet.html.
Cautionary Statement
This document does not constitute an offer to sell or a solicitation of an offer to buy any of our securities. This document contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements contained herein can be identified by the use of forward-looking terminology such as "believes," "expects," "may," "will," "should," or "anticipates," or the negative thereof or other variations thereon or comparable terminology, or by discussions of strategy that involve risks and uncertainties. We wish to caution the reader that these forward-looking statements that are not historical facts, are only predictions. No assurances can be given that the future results indicated, whether expressed or implied, will be achieved.
